IMPAKT 2013: Long-term effectiveness of SERMs for preventing breast cancer





The interactive transcript could not be loaded.


Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on May 20, 2013

World-leading epidemiologist Prof Jack Cuzick talks to ecancer about his paper in the Lancet confirming that selective estrogen receptor modulators (SERMs) are both effective and safe for preventing breast cancer in women who are at high risk of the disease but who are not ill.

There has been caution about using tamoxifen and raloxifene (both SERMs) following scare stories in the US: Prof Cuzick's meta analysis addreses this and brings hope of avoiding a third of breast cancers.

Comments are disabled for this video.
When autoplay is enabled, a suggested video will automatically play next.

Up next

to add this to Watch Later

Add to

Loading playlists...